Hyperuricemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Topiroxostat is a selective xanthine oxidoreductase (XOR) inhibitor for the management of hyperuricemia in patients with or without gout.
|
31733581 |
2020 |
Hyperuricemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Plasma XOR activity has been shown to be associated with obesity, smoking, liver dysfunction, hyperuricemia, dyslipidemia and insulin resistance.
|
30516339 |
2019 |
Hyperuricemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These data demonstrate that hepatocyte XOR activity is a critical determinant of systemic UA homeostasis, that deletion of hepatocyte <i>Xdh</i> is sufficient to prevent systemic HyUA of obesity, and that neither prevention nor correction of HyUA improves insulin resistance/dyslipidemia in obesity.
|
30936145 |
2019 |
Hyperuricemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Xanthine oxidase (XO) is a form of xanthine oxidoreductase, a type of enzyme that plays a key role in the induction of hyperuricemia and raising superoxide radical level in blood.
|
31639647 |
2019 |
Hyperuricemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Despite the availability of different drugs to inhibit in vivo XOR activity, the complexity of XOR inhibition effects should be carefully considered before clinical application, save in the case of symptomatic hyperuricemia.
|
30576922 |
2019 |
Hyperuricemia
|
0.600 |
Biomarker
|
disease |
CTD_human |
Potential cow milk xanthine oxidase inhibitory and antioxidant activity of selected phenolic acid derivatives.
|
29071757 |
2018 |
Hyperuricemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Human Xanthine oxidoreductase (HsXOR) is considered to be a pharmacological target for the treatment of hyperuricemia.
|
29906649 |
2018 |
Hyperuricemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Excited-UA study would provide novel evidence for the clinical relevancy of xanthine oxidoreductase inhibitor treatment in patients with chronic heart failure and hyperuricemia.
|
29916098 |
2018 |
Hyperuricemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
We attempted to examine the uric acid-lowering effect and the renoprotective effect of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia in this pilot study.
|
29372470 |
2018 |
Hyperuricemia
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
ALLO can significantly decrease serum uric acid levels (P<0.01) and raise XDH/XO mRNA expression levels in the liver tissue of tree shrews with HUA.
|
28302963 |
2017 |
Hyperuricemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS GPS may be an effective treatment for hyperuricemia via a decrease in xanthine oxidoreductase through the XOD/XDH system; and via an increase in urate excretion through regulating URAT1, GLUT9, and OAT1 transporters.
|
28258276 |
2017 |
Hyperuricemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, 50 mg/kg/d baicalein treatment significantly suppressed the viability of xanthine oxidoreductase in hyperuricemia mouse model.
|
28445133 |
2017 |
Hyperuricemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, the therapeutics currently approved for the treatments of hyperuricemia are outlined and an overview regarding novel, currently researched XOR inhibitors is provided.
|
28413972 |
2017 |
Hyperuricemia
|
0.600 |
Therapeutic
|
disease |
RGD |
Cd exposure induced hyperuricemia with renal XOR hyperactivity and UA excretion dysfunction in rats.
|
22690247 |
2012 |